Archives: Search / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015
Jan 4, 2021 - Safety Review Committee approved Phase 1b expansion cohorts in study arm evaluating zandelisib in combination with zanubrutinib in various B-cell maligniancies -
|
Nov 10, 2020 --Expands Clinical Development of Zandelisib to New Indications and Earlier Lines of Treatment--
|
Sep 9, 2020 - Strong cash position of ~$183 million at start of fiscal year 2021 -
|
Jul 2, 2020 Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis
|
May 26, 2020 - Event scheduled for June 2, 2020 at 8am ET; featuring leading KOL Matthew Matasar, M.D. -
|
May 13, 2020 - Data to be Featured in the American Society of Clinical Oncology Annual 2020 Virtual Scientific Program on May 29, 2020 at 8:00 a.m. EDT -
|
- 83% overall response rate in patients with relapsed or refractory follicular lymphoma -
|
